Tech Transfer eNews Blog

U of Birmingham spinoff develops novel treatment for rare neurological disorder

By Jesse Schwartz
Published: July 10th, 2019

A spinoff of the University of Birmingham (UK) is developing an innovative new treatment for Idiopathic Intracranial Hypertension (IIH).

Invex Therapeutics Ltd. aims to repurpose the already approved drug Exenatide to target IIH, which causes disabling daily headaches and severely raises pressure around the nerves in the eye, sometimes resulting in permanent vision loss.

The start-up is based on the research of Professor Alexandra Sinclair, who has shown in animal studies that Exenatide rapidly and dramatically decreases intracranial pressure.

“There is a clear unmet need for a dedicated, safe and effective treatment for IIH,” says Sinclair. “Although IIH is a relatively rare condition, our work has shown that its incidence has increased by 350% in the last 10 years, and it is associated with significant morbidity and a significant reduction in patients’ quality of life.”

Invex has received support from University of Birmingham Enterprise, the school’s commercialization arm, and has obtained patents on the treatment. The start-up has also successfully completed an IPO on the Australian Stock Exchange that raised $A12 million ($US8.3 million) at an issue price of $A0.40 per share. It plans to use the funds to conclude an ongoing clinical study.

James Wilkie, CEO of University of Birmingham Enterprise, comments, “We are delighted with the success of this capital raising and the assignation of IP to a company that is committed to the rapid development of a novel treatment in an area of high unmet medical need.”

Source: University of Birmingham News

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment